Skip to content

Alendronate Sodium Tablet

Also called Alendronic Acid Sodium Tablet in India, Australia, the UK and most countries outside the US.

Alendronate Sodium Tablet comes in 2 pill versions in our database, in 2 strengths, from 1 manufacturer. Check the imprint to tell them apart.

Alendronate Sodium Tablet pill images

35 mg 1 pill

70 mg 1 pill

What is Alendronate Sodium Tablet used for?

Alendronate Sodium Tablet is used for osteoporosis (weak bones).

Official uses from the US prescribing label

Treatment of Osteoporosis in Postmenopausal Women

Alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures).

Prevention of Osteoporosis in Postmenopausal Women

Alendronate sodium tablets are indicated for the prevention of postmenopausal osteoporosis.

Treatment to Increase Bone Mass in Men with Osteoporosis

Alendronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis

.

Treatment of Glucocorticoid-Induced Osteoporosis

Alendronate sodium tablets are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density.

Treatment of Paget's Disease of Bone

Alendronate sodium tablets are indicated for the treatment of Paget’s disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.

Important Limitations of Use

The optimal duration of use has not been determined. The safety and effectiveness of alendronate sodium tablets for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

From the FDA-approved label on DailyMed (published Sep 12, 2025).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.